Recently, research found that DCs produced high levels of IFN-γ and TNF-α when pulsed with tumor-associated antigens (TAAs) and the percentage of regulatory T cells (Tregs) decreased in patients after DC-CTLs therapy [73], which may be a strategy to elicit effective immune response by combining AFP with other TAAs. This evidence concerns the gene IFNG and neoplasm.